Radiopharm Theranostics Limited (RADX) Financial Ratios
4 years of historical data (2021–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.93
↑+24% vs avg
5yr avg: 0.75
30Y Low0.8·High0.8
ROE
↓
-109.2%
↑-24% vs avg
5yr avg: -88.2%
30Y Low-131%·High-48%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RADX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Radiopharm Theranostics Limited currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Market Cap | $33M | $32M | — | — | — |
| Enterprise Value | $12M | $3M | — | — | — |
| P/E Ratio → | -1.09 | — | — | — | — |
| P/S Ratio | 12.47 | 8.86 | — | — | — |
| P/B Ratio | 0.93 | 0.75 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RADX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| EV / Revenue | — | 0.84 | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
RADX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Radiopharm Theranostics Limited earns an operating margin of -1050.6%. Operating margins have expanded from -11803.3% to -1050.6% over the past 3 years, signaling improving operational efficiency. A negative ROE of -109.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Gross Margin | 1.1% | 1.1% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -1050.6% | -1050.6% | -12238.4% | -11803.3% | -225527.7% |
| Net Profit Margin | -1055.3% | -1055.3% | -16024.3% | -11838.6% | -343550.9% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| ROE | -109.2% | -109.2% | -131.5% | -63.8% | -48.2% |
| ROA | -48.4% | -48.4% | -65.2% | -43.7% | -36.4% |
| ROIC | -254.1% | -254.1% | -128.8% | -74.1% | -41.5% |
| ROCE | -60.6% | -60.6% | -63.0% | -50.3% | -26.4% |
RADX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $29M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.68 | -0.68 | -0.26 | -0.43 |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | -584.59 | -584.59 | -56.96 | -400.83 | -2.13 |
Net cash position: cash ($29M) exceeds total debt ($0)
RADX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Radiopharm Theranostics Limited's current ratio of 2.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.23x to 2.67x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Current Ratio | 2.67 | 2.67 | 1.30 | 1.23 | 3.46 |
| Quick Ratio | 2.67 | 2.67 | 1.30 | 1.23 | 3.46 |
| Cash Ratio | 1.95 | 1.95 | 1.06 | 0.88 | 3.42 |
| Asset Turnover | — | 0.04 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | 1044.75 | 1204.45 | 5578.03 | 2334.50 |
RADX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Radiopharm Theranostics Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $1M | $1M | $1M |
Peer Comparison
Compare RADX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RADXYou | $33M | -1.1 | — | — | 1.1% | -1050.6% | -109.2% | -254.1% | — |
 RNW | $1B | 46.7 | 11.3 | — | 91.1% | 53.5% | 3.0% | 4.9% | 10.1 |
 RNAZ | $7M | -0.2 | — | — | — | — | — | — | — |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 PRTC | $41M | -0.4 | — | — | 100.0% | -2114.7% | -30.8% | -66.9% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 IART | $1B | -2.0 | 13.0 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 NVS | $277B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
See RADX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RADX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RADX vs RNW
Side-by-side business, growth, and profitability comparison vs ReNew Energy Global Plc.
Start ComparisonRADX — Frequently Asked Questions
Quick answers to the most common questions about buying RADX stock.
What is Radiopharm Theranostics Limited's P/E ratio?
Radiopharm Theranostics Limited's current P/E ratio is -1.1x. This places it at the 50th percentile of its historical range.
What is Radiopharm Theranostics Limited's ROE?
Radiopharm Theranostics Limited's return on equity (ROE) is -109.2%. The historical average is -88.2%.
Is RADX stock overvalued?
Based on historical data, Radiopharm Theranostics Limited is trading at a P/E of -1.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Radiopharm Theranostics Limited's profit margins?
Radiopharm Theranostics Limited has 1.1% gross margin and -1050.6% operating margin.